Sanofi

Sanofi-aventis

Marion Schneider

Stefanie Keil

Hans-Ludwig Schaefer

Wolfgang Wendler

Ercole Rao

Christian Lange

Maike Glien

Stefan Guessregen

Christian Beil

Cendrine Lemoine

Jochen Beninga

Wulf Dirk Leuschner

Joerg Birkenfeld

Chantal Carrez

Katja Kroll

Wulf-Dirk Leuschner

Peter Wonerow

Werner Dittrich, I

Jana Albrecht

Cédric Barriere

Stéphane Guerif

Marie-Cécile Wetzel

The present invention relates to a method for producing a fusion polynucleotide encoding a polypeptide of interest. The method comprises the steps of providing a first polynucleotide and a second polynucleotide, and contacting said first polynucleotide and second polynucleotide with a type IIs restriction endonuclease and a ligase under conditions that allow for the cleavage of the first polynucleotide and second polynucleotide by said type IIs restriction endonuclease and the ligation of the resulting cleavage products, thereby producing the fusion polynucleotide encoding the polypeptide of interest. The first polynucleotide comprises the 5' portion of an intron, and the second polynucleotide comprises the 3&#x2032; portion of an intron. Further envisaged by the present invention is a polynucleotide encoding a polypeptide of interest, which, when transcribed in a eukaryotic host cell, is transcribed into a transcript comprising at least five introns which are heterologous to said polynucleotide.

Intron-based universal cloning methods and compositions

The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.

Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123

The invention relates to substituted sulfonylpyrrolidines of the formula I and to the physiologically tolerated salts thereof, as well as to their use as medicaments.

Sulfonyl pyrrolidines, method for producing the same and their use as drugs

Growing community of inventors

Hofheim, Germany

Marion Schneider